<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795478</url>
  </required_header>
  <id_info>
    <org_study_id>sunQKT6660</org_study_id>
    <nct_id>NCT05795478</nct_id>
  </id_info>
  <brief_title>Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery</brief_title>
  <official_title>Effects of Oxycodone Combined With Pregabalin on Chronic Postsurgical Pain in Spinal Surgery: a Randomized Control, Double-blinded, Factorial Design Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic postoperative pain is one of the common perioperative complications, which seriously&#xD;
      affects the prognosis of patients. Currently, no specific perioperative pain management&#xD;
      strategy has been found to be effective in preventing and treating chronic postoperative pain&#xD;
      in patients undergoing spinal surgery. At present, oxycodone has been widely recognized in&#xD;
      different surgical populations for the control of acute postoperative pain, but its&#xD;
      contribution to chronic postoperative pain remains unknown. Meanwhile, whether pregabalin can&#xD;
      reduce the occurrence of chronic postoperative pain remains controversial, and whether the&#xD;
      combination of the two drugs can control the occurrence of chronic postoperative pain in a&#xD;
      more comprehensive way remains unknown. Therefore, we intend to conduct this&#xD;
      randomized-controlled, factorial design study to determine the efficacy and safety of&#xD;
      oxycodone combined with pregabalin in the treatment of chronic postoperative pain in patients&#xD;
      undergoing spinal surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of CPSP</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>The incidence of chronic postsurgical pain, the CPSP was defined as an NRS score &gt;3 (0~10).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Chronic Post Operative Pain</condition>
  <condition>Oxycodone</condition>
  <condition>Pregabalin</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Combined group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxycodone+Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oxycodone+placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NS+Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NS+placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone and Pregabalin</intervention_name>
    <description>Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1~7,75mg QD for POD8~14</description>
    <arm_group_label>Combined group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone and placebo capsules</intervention_name>
    <description>Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point</description>
    <arm_group_label>Oxycodone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin and NS</intervention_name>
    <description>Pregabalin: 150mg preoperatively, 75mg BID for POD1~7,75mg QD for POD8~14 NS: Equal volume NS for 3 days postoperatively</description>
    <arm_group_label>Pregabalin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo capsules and NS</intervention_name>
    <description>placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing elective spinal surgery&#xD;
&#xD;
          -  Ages equal to or more than 18 years old&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous allergic history to gabapentinoids or oxycodone;&#xD;
&#xD;
          -  Patients with aphasia or inability to cooperate with scales assessments;&#xD;
&#xD;
          -  Patients with a diagnosed history of psychiatric disorder;&#xD;
&#xD;
          -  Known severe insufficiency of vitals(such as heart failure/renal dysfunction/hepatic&#xD;
             failure);&#xD;
&#xD;
          -  Patients treated with gabapentin/pregabalin in the last three months;&#xD;
&#xD;
          -  History of drug abuse;&#xD;
&#xD;
          -  Body Mass Index more than 35 kg/„é°;&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <phone>8610-59976660</phone>
    <email>ruquan.han@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@ccmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 31, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 31, 2023</last_update_submitted>
  <last_update_submitted_qc>March 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Director of Anesthesiology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

